GP方案与TP方案一线治疗晚期非小细胞肺癌的临床观察被引量：14

Clinical observation of original chemotherapy for advanced non-small cell lung cancer between GP regimen and TP regimen

暂未订购

导出

摘要目的:探讨GP方案和TP方案对初治的晚期非小细胞肺癌(NSCLC)的疗效和毒性。方法:72例晚期NSCLC(ⅢB期50例,Ⅳ期22例)随机分成GP组和TP组,入组的每例患者接受至少2个周期以上的GP或TP同样方案的化疗,比较两组不同化疗方案的近期疗效和毒副反应,以及1、2年的生存率。结果:GP和TP两组近期疗效的有效率分别为44.4%和47.2%,两组中位生存期分别为8.7月和8.5月,1年生存率分别为16.6%和19.4%,2年生存率分别为8.3%和11.1%。两组资料统计学处理均无显著性差异。毒副反应方面,GP组以血小板降低为主,TP组以白细胞降低为主,均在可耐受的范围内。结论:GP和TP两种化疗方案对晚期NSCLC均有较好的临床疗效,化疗毒副反应虽有所不同,但均可耐受。因此GP和TP两种化疗方案均可作为晚期NSCLC的一线治疗方案。 Objective：TO investigate the efficacy and toxicity of the GP regimen and TP regimen on advanced non-small cell lung cancer. Methods：Seventy-two patients with advanced non-small cell lung cancer were divided into the GP and the TP group randomly. In all case ,50 patients were in stage Ⅲ B, 22 patients in stage Ⅳ ,all the patients had accepted intravenous chemotherapy and preponderated over 2cycles. A clinical observation on short term effectiveness adverse effects and the 1-,2-year survival rate were cartied out in two groups. Resets：The short term effective rate for advanced non-small cell lung cancer in GP group and TP group was 44.4% and 47.2%, respectively. The median survival time was 8.7 months and 8. 5 months, respectively. 1-year survival rate was 16. 6% and 19.4% ,respectively. 2-year survival rate was 8. 3% and 11.1%. The short term effectiveness and the 1,2-year-survival state in two groups had no statistically significant difference （ P 〉 0. 05 ）. In the adverse effects of treatment, the major cytotoxicity was thrombocytopenia in GP group and leukopenia in TP group but they were tolerable. Conclusion： Both GP regimen and TP regimen on advanced non-small cell lung cancer show more effectiveness. The side effects of the two regimens are different but all adverse reactions are tolerable, they could become the original chemotherapy in advanced non-small cell lung cancer.

作者杭达明谢国栋张葆春

机构地区南通市肿瘤医院放疗科南通市肿瘤医院内科

出处《临床肿瘤学杂志》 CAS 2008年第2期133-136,共4页 Chinese Clinical Oncology

关键词非小细胞肺癌化学治疗吉西他滨紫杉醇顺铂 Non-small cell lung cancer Chemotherapy Gemcitabine Paclitaxel Cisplatin

分类号 R730.53 [医药卫生—肿瘤]

引文网络
相关文献

参考文献10

1Laskin JJ, Sandler AB. First-line treatment for advanced nonsmall cell lung cancer[ J]. Oncology (Williston Park) ,2005,19 ( 13 ) : 1671 - 1676.
2Spigel DR, Greco FA. Chemotherapy in metastatic and locally advanced non-small cell lung cancer[ J]. Simin Surg Oncol,2003, 21(2) :98 -110.
3Waechter F,Passweg J, Tamm M, et al. Significant progress in palliative treatment of non-small cell lung cancer in the past decade[ J ]. Chest,2005,127 (3) :738 - 747.
4Manegold C. Gemcitabine (Gemzar) in non-small cell lung cancer[J]. Expert Rev Anticancer Ther,2004,4(3) :345 -360.
5贾博珍,鲁云兰.临床医师治疗全书[M].2版.北京:北京医科大学出版社,2003:686-687.
6Belderbos JS, De Jaeger K, Heem SWD, et al. First results of a phase Ⅰ/Ⅱ dose escalation trial in non-small cell lung cancer using three-dimensional radiotherapy[J]. Radiother Oncol, 2003,66 (2) :119 - 126.
7崔同建,刘振华,陈峥,张桂枫.晚期非小细胞肺癌4种化疗方案临床对照研究[J].肿瘤学杂志,2006,12(2):136-138. 被引量：22
8孙燕，周际昌．临床肿瘤内科学手册[M]．北京：人民卫生出版社，2003．556-567．
9刘联,王秀问,黎莉,张昕,张文东,于学军.含顺铂的三组联合化疗方案治疗晚期非小细胞肺癌的随机对照临床研究[J].癌症,2006,25(8):990-994. 被引量：93
10Smit EF, Van Meerbeeck JP, Lianes P,et al. Throe-arm randomized study of two cisplatin-based regiments and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975 [ J]. J Clin Oncol, 2003,21 ( 21 ) :3909 -3910.

二级参考文献21

1刘敏知,陈颖兰,邓觐云,王迪进,徐炎良.泰素帝联合顺铂与长春瑞滨联合顺铂治疗晚期非小细胞肺癌的临床比较[J].临床肿瘤学杂志,2005,10(3):252-254. 被引量：10
2高勇,石昭泉,曹传武,朱长力,郭静.泰索帝联合顺铂及健择联合顺铂治疗非小细胞肺癌随机对照临床研究[J].癌症,2005,24(8):985-989. 被引量：19
3Raez L E, Lilenbaum R. New developments in chemotherapy for advanced non-small cell lung cancer [J]. Curr Opin Oncol,2006,18(2) : 156-161.
4Laskin J J, Sandier A B. First-line treatment for advanced non-small-cell lung cancer [J]. Oncology (Williston Park), 2005,19(13) : 1671-1680.
5Le Chevalier T, Brisgand D, Pujol J L, et al. Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer[J].Bull Cancer, 1996,83 (5) : 385-394.
6Chen C H, ChangW C, Lin M C, et al. Phase Ⅱ study of paclitaxel (Genaxol) and cisplatin combination in treating Chinese patients with advanced non-small cell lung cancer(NSCLC) [J]. Lung Cancer, 2002,38( 1 ) :91-96.
7Bretti S, Manzin E, Loddo C, et al. Gemcitabine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a phase Ⅱ study [J]. Anticancer Res, 2002,2(5):3039-3043.
8Stathopoulos G P, Rigatos S, Malamos N A. Paclitaxel combined with cisplatin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cisplatin [J]. Oncol Rep, 1999,6(4):797-800
9Johnson D H, Chang A Y, Ettinger D S, et al. Recent advances with chemotherapy for NSCLC: the ECOG experience. Eastern Cooperative Ontology Group [J]. Ontology (Williston Park),1998,12( 1 Suppl 2) :67-70.
10Schiller J H, Harrington D, Belani C P, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002,346(2):92-98.